ARTICLE | Company News
Mayo Clinic, TapImmune deal
June 13, 2016 7:00 AM UTC
TapImmune exercised an option under a 2010 deal with Mayo to license exclusive, worldwide rights to develop and commercialize Mayo’s HER2/neu peptide vaccine ( TPIV100) in cancers overexpressing HER2 antigens. ...